A pre-print RCT in healthy adults suggests that a multi-target supplement can improve endothelial function and arterial stiffness.
The longevity sector has spent the better part of a decade making promises towards clinical rigour; in practice, this transition was uneven – sometimes convincing, but more effort. now, NEW published preprint data from a randomized, double-blind, placebo-controlled trial examining the effects of a multicomponent nutritional intervention on vascular aging in adults aged 40 years and older. The results are early, of course, but they’re also structured—providing measurable changes in several established markers of cardiovascular function, rather than the usual “survival” promises.
Funded by NOVOS (although the company had no role in the initial data collection or analysis) and in University of Surrey and led by Professor Christian Hayes, the study enrolled 61 apparently healthy participants, 43 of whom completed the six-month protocol. The endpoint was flow-mediated dilation (FMD)—a sensitive and functional measure of how well the endothelium actually responds to stress—while secondary endpoints tracked carotid-femoral pulse wave velocity (PWV) and systolic blood pressure. Across the board, the intervention group showed improvements over placebo, which the authors describe as not just statistical noise, but a coherent change in the underlying biology of vascular aging (1).
Longevity.Technology: Longevity interventions aimed at prevention are increasingly sitting on a fault line – between the healthy world, which rarely meets sweeping claims it doesn’t enjoy, and the clinical world, which tends to require repetition, peer review and a little less enthusiasm. That’s what makes such information interesting. A randomized, double-blind, placebo-controlled trial in healthy adults over 40 years of age showing improvement in flow-through expansion, pulse wave velocity, and systolic blood pressure is none; in the category of additions more accustomed to the music of the metabolic mood than the correct vascular endpoints, it shows significant tone changes. For now, the preprint remains the preprint—small, single-centered, and built around surrogate markers, not hard outcomes, even though those markers may be relevant to cardiovascular aging. The more interesting question, perhaps, is whether the extra space is what it is when it grows: the promise of less breathing, more measured biology; less anti-aging pantomime, more information that can at least survive contact with investigation. If longevity is serious about prevention—and it should be—then interventions aimed at middle-aged adults will need exactly this kind of scientific foundation, even if it is not yet clear. The challenge now is not just to post encouraging numbers, but to show that they endure, replicate and translate.
Studies in vascular function
At the end of six months, the data showed some changes: the endothelial function in the intervention group improved by 2.9% compared to the placebo. Arterial stiffness, as measured by carotid-femoral pulse wave velocity, decreased by 1.18 m/s, while systolic blood pressure decreased by 6.1 mmHg.1).
Individually, these changes are within the range considered clinically significant in vascular studies; for context, the improvements in median dilatation (FMD) and pulse wave velocity (PWV) reported here are actually greater than what is typically seen in resistance training or acute interval training. Together, they begin to draw a logical pattern rather than an isolated tragedy. Endothelial function reflects the “software” of the system – nitric oxide signaling and vascular reactivity, while pulse wave velocity captures the “hardness” or structural stiffness along the arterial tree. Blood pressure essentially combines the two and represents the entire system under load. That all three markers moved in the same direction lends some internal consistency to the findings—it’s not conclusive evidence of a reverse aging trajectory, but it’s a resonant signal worth noting.
As senior author Dr. Christian Hayes, professor of cardiovascular medicine at the University of Surrey, says, “Together, the improvements in endothelial function, arterial elasticity and systolic pressure point to a coordinated pattern of favorable changes in the biology of vascular aging.”
Meanwhile, lipid profiles remained unchanged—an important detail (1). Its effect appears to be mediated by endothelial and hemodynamic pathways rather than by lipid modulation, reminding that cardiovascular risk is not a single axis but a network.
Targeted systems, not one-size-fits-all solutions
The formula itself is implicitly plural. Rather than isolating a single compound, it integrates many bioactives that act on oxidative stress, mitochondrial function, inflammation, and nitric oxide signaling—a design philosophy derived directly from the hallmarks of aging.
There is a certain harmony in this relationship; Arterial aging does not proceed in one way, so why intervene? At the same time, it makes interpretation difficult. Twelve compounds, each with plausible mechanisms (including alpha-ketoglutarate, fisetin, pterostilbene), complicate attribution. Biology can be systemic; The evidence, of course, is still not so strong.
Prevention in action
Perhaps most interesting is who was studied. Not patients, not high-risk groups, but generally healthy middle-aged adults—individuals in whom vasoconstriction is occurring but not yet clinically expressed (1). This is where prevention lives, in theory; it also becomes more difficult to detect the signal there.
Small changes. Early shifts.
In this context, even modest movements in validated biomarkers carry weight. Epidemiological data suggest that relatively small reductions in systolic blood pressure are associated with significant differences in cardiovascular risk; Endothelial function, while more indirect, has similar prognostic associations.
Hayes puts it more directly: “This trial provides unique human evidence that a multifaceted nutritional strategy can affect the very biology of cardiovascular aging. The magnitude and consistency of these effects across multiple cardiovascular endpoints is unusual for a nutritional intervention in a healthy population.”
Interpretation of primary signals
However, caution is in order. This is a single-center study with a modest sample size; attrition reduced the number of participants included in the final analysis. Endpoints, although well established, are surrogate measures—informative but not definitive. And, as of pre-print, the work has yet to undergo peer review.
None of this invalidates the findings. It just places them – early, structured, incomplete.
Among the categories
It’s a quieter shift in all of this. Nutritional interventions, long located between lifestyle advice and commercial wellness, at least in places adopt the methodological language of clinical science. Randomization. Blindness. Fixed points.
It changes the conversation. Not completely, not yet – but enough to notice.
Where the signal leads
If longevity is critical to moving upstream, then interventions must demonstrate not only that they can induce biomarkers over months, but that they can alter trajectories over years. Such evidence is slowly piling up.
Right now, the direction is clearer than the destination.
Photo taken from NOVOS
